Figure 3.

TUDCA Treatment Reverses the Anti-Tumor Effect of HCD Feeding on KRAS-Driven Lung Tumors

(A) Timetable of mouse treatments.

(B) Representative images of lung sections stained with H&E.

(C) Histograms indicating quantification of tumor burden, size, and number.

(D) mRNA levels of Xbp1s.

(E) Representative immunoblot against phospho- and total IRE1α and eIF2α.

(F) Representative images of lung sections stained with anti-p-H3 (p-H3-positive cells in brown) and histograms indicating the percentage of p-H3-positive cells/tumor cells of microdissected tumors.

Data shown in (B)–(F) are from 29-week-old Kras^G12D mice treated as indicated in (A) (females, n = 5/group). Error bars represent SEM. Statistical analyses were done using one-way ANOVA (Tukey’s post test). ^∗p < 0.05, ^∗∗p < 0.01. See also Figure S3.